Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat heart in association with anti-apoptotic pathways of survival

European Journal of Pharmacology

Volumn 628, Issue 1-3, 2010, Pages 132-139

  Kim, Hyun Soo ^a   Cho, Jang Eun ^b   Hwang, Ki Chul ^c   Shim, Yeon Hee ^b   Lee, Jung Hwa ^b   Kwak, Young Lan ^b  

^a Ewha Womans University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Cardiovascular Research Institute   (South Korea)

Author keywords

Diabetes mellitus; Ischemia reperfusion; Remifentanil

Indexed keywords

CALCIUM ION; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; REMIFENTANIL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; WILD TYPE;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CELL SURVIVAL; DIABETES MELLITUS; GENE EXPRESSION REGULATION; HEART; HEMODYNAMICS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL INFARCTION; MYOCARDIUM; PHOSPHORYLATION; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SARCOPLASMIC RETICULUM;

EID: 73649115943     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.032     Document Type: Article

References (50)

1. Abbud Z.A., Shindler D.M., Wilson A.C., Kostis J.B., and Myocardial Infarction Data Acquisition System Study Group. Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myocardial infarction: a statewide study. Am. Heart J. 130 (1995) 51-58
2. Al-Maqhrebi M., Benter I.F., and Diz D.I. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol. Res. 59 (2009) 263-268
3. Arai M., Matsui H., and Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ. Res. 74 (1994) 555-564
4. Bazargan M., Faghihi M., and Chitsaz M. Importance of timing of magnesium administration in the isolated ischemic-reperfused rat heart: role of KATP channels. Physiol. Res. 57 (2008) 839-846
5. Choi K.M., Zhong Y., Hoit B.D., Grupp I.L., Hahn H., Dilly K.W., Guatimosim S., Lederer W.J., and Matlib M.A. Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H1398-H1408
6. Cleveland Jr. J.C., Meldrum D.R., Cain B.S., Banerjee A., and Harken A.H. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 96 (1997) 29-32
7. Dhalla N.S., Pierce G.N., Innes I.R., and Beamish R.E. Pathogenesis of cardiac dysfunction in diabetes mellitus. Can. J. Cardiol. 1 (1985) 263-281
8. Ebel D., Mullenheim J., Frassdorf J., Heinen A., Huhn R., Bohlen T., Ferrari J., Sudkamp H., Preckel B., Schlack W., and Thamer V. Effect of acute hyperglycaemia and diabetes mellitus with and without short-term insulin treatment on myocardial ischaemic late preconditioning in the rabbit heart in vivo. Pflugers Arch. 446 (2003) 175-182
9. Fein F.S., and Sonnenblick E.H. Diabetic cardiomyopathy. Prog. Cardiovasc. Dis. 27 (1985) 255-270
10. Feng J., Lucchinetti E., Ahuja P., Pasch T., Perriard J.C., and Zaugg M. Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology 103 (2005) 987-995
11. Ghosh S., Standen N.B., and Galinianes M. Failure to precondition pathological human myocardium. J. Am. Coll. Cardiol. 37 (2001) 711-718
12. Glass P.S. Remifentanil: a new opioid. J. Clin. Anesth. 7 (1995) 558-563
13. Gross E.R., Hsu A.K., and Gross G.J. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 56 (2007) 127-136
14. Hausenloy D.J., and Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res. 61 (2004) 448-460
15. Herlitz J., Wognsen G.B., Emanuelsson H., Haglid M., Karlson B.W., Karlsson T., Albertsson P., and Westberg S. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 19 (1996) 698-703
16. 2+ pump activity during diabetes mellitus. Am. J. Physiol. 252 (1987) H540-H544
17. Howarth F.C., Qureshi A., and Singh J. Effects of acidosis on ventricular myocyte shortening and intracellular Ca2+ in streptozotocin-induced diabetic rats. Mol. Cell. Biochem. 261 (2004) 227-233
18. Huhn R., Heinen A., Weber N.C., Hollmann M.W., Schlack W., and Preckel B. Hyperglycaemia blocks sevoflurane-induced postconditioning in the rat heart in vivo: cardioprotection can be restored by blocking the mitochondrial permeability transition pore. Br. J. Anaesth. 100 (2008) 465-471
19. 2+ overload in ischemic heart and hypoxic neonatal cardiomyocytes. J. Steroid Biochem. Mol. Biol. 91 (2004) 131-138
20. Javadov S.A., Lim K.H., Kerr P.M., Suleiman M.S., Angelini G.D., and Halestrap A.P. Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc. Res. 45 (2000) 360-369
21. 2+ overload in ischemia-reperfused heart and hypoxiareoxygenated cardiomyocytes. Eur. J. Pharmacol. 535 (2006) 212-219
22. Kersten J.R., Schmeling T.J., Orth K.G., Pagel P.S., and Warltier D.C. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am. J. Physiol. 275 (1998) H721-H725
23. Kersten J.R., Montgomery M.W., Ghassemi T., Gross E.R., Toller W.G., Pagel P.S., and Warltier D.C. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am. J. Physiol. Heart Circ. Physiol. 280 (2001) H1744-H1750
24. Kluck R.M., Bossy-Wetzel E., Green D.R., and Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
25. Lopaschuk G.D., Tahiliani A.G., Vadlamudi R.V., Katz S., and McNeill J.H. Cardiac sarcoplasmic reticulum function in insulin- or carnitine-treated diabetic rats. Am. J. Physiol. 245 (1983) H969-H976
26. Makino N., Dhalla K.S., Elimban V., and Dhalla N.S. Sarcolemmal Ca2+ transport in streptozotocin-induced diabetic cardiomyopathy in rats. Am. J. Physiol. 253 (1987) E202-E207
27. Marber M.S., Latchman D.S., Walker J.M., and Yellon D.M. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88 (1993) 1264-1272
28. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
29. Patel S.S., and Spencer C.M. Remifentanil. Drugs 52 (1996) 417-427 discussion 428
30. Paulson D.J. The diabetic heart is more sensitive to ischemic injury. Cardiovasc. Res. 34 (1997) 104-112
31. Peart J.N., Gross E.R., and Gross G.J. Opioid-induced preconditioning: recent advances and future perspectives. Vasc. Pharmacol. 42 (2005) 211-218
32. Penpargkul S., Fein F., Sonnenblick E.H., and Scheuer J. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J. Mol. Cell. Cardiol. 13 (1981) 303-309
33. Pierce G.N., and Russell J.C. Regulation of intracellular Ca2+ in the heart during diabetes. Cardiovasc. Res. 34 (1997) 41-47
34. Qi J.S., Kam K.W., Chen M., Wu S., and Wong T.M. Failure to confer cardioprotection and to increase the expression of heat-shock protein 70 by preconditioning with a kappa-opioid receptor agonist during ischaemia and reperfusion in streptozotocin-induced diabetic rats. Diabetologia 47 (2004) 214-220
35. Schaffer S.W., and Mozaffari M. Abnormal mechanical function in diabetes: relation to myocardial calcium handling. Coron. Artery Dis. 7 (1996) 109-115
36. Schultz J.E., and Gross G.J. Opioids and cardioprotection. Pharmacol. Ther. 89 (2001) 123-137
37. Smith J.W., Marcus F.I., and Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am. J. Cardiol. 54 (1984) 718-721
38. Tanaka K., Kehl F., Gu W., Krolikowski J.G., Pagel P.S., Warltier D.C., and Kersten J.R. Isoflurane-induced preconditioning is attenuated by diabetes. Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H2018-H2023
39. Tanaka K., Ludwig L.M., Kersten J.R., Pagel P.S., and Warltier D.C. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 100 (2004) 707-721
40. Temsah R.M., Netticadan T., Chapman D., Takeda S., Mochizuki S., and Dhalla N.S. Alterations in sarcoplasmic reticulum function and gene expression in ischemic-reperfused rat heart. Am. J. Physiol. 277 (1999) H584-H594
41. Tsuruta F., Masuyama N., and Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J. Biol. Chem. 277 (2002) 14040-14047
42. Uecker M., Da Silva R., Grampp T., Pasch T., Schaub M.C., and Zaugg M. Translocation of protein kinase C isoforms to subcellular targets in ischemic and anesthetic preconditioning. Anesthesiology 99 (2003) 138-147
43. Wold L.E., Dutta K., Mason M.M., Ren J., Cala S.E., Schwanke M.L., and Davidoff A.J. Impaired SERCA function contributes to cardiomyocyte dysfunction in insulin resistant rats. J. Mol. Cell. Cardiol. 39 (2005) 297-307
44. Xu G., Takashi E., Kudo M., Ishiwata T., and Naito Z. Contradictory effects of short- and long-term hyperglycemias on ischemic injury of myocardium via intracellular signaling pathway. Exp. Mol. Pathol. 76 (2004) 57-65
45. Yousif M.H., Benter I.F., Abul A.H., Abraham S., Walther T., and Akhtar S. Inhibition of Ras-GTPase signaling by FPTIII ameliorates development of cardiovascular dysfunction in diabetic-hypertensive rats. Vasc. Pharmacol. 49 (2008) 151-157
46. Yu C.K., Li Y.H., Wong G.T., Wong T.M., and Irwin M.G. Remifentanil preconditioning confers delayed cardioprotection in the rat. Br. J. Anaesth. 99 (2007) 632-638
47. Zhang Y., Irwin M.G., and Wong T.M. Remifentanil preconditioning protects against ischemic injury in the intact rat heart. Anesthesiology 101 (2004) 918-923
48. Zhang Y., Chen Z.W., Girwin M., and Wong T.M. Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats. Acta Pharmacol. Sin. 26 (2005) 546-550
49. Zhong Y., Ahmed S., Grupp I.L., and Matlib M.A. Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H1137-H1147
50. Zhu L., Yu Y., Chua B.H., Ho Y.S., and Kuo T.H. Regulation of sodium-calcium exchange and mitochondrial energetics by Bcl-2 in the heart of transgenic mice. J. Mol. Cell. Cardiol. 33 (2001) 2135-2144